Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,319 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Targeted agent Clear all
Completed Not applicable Interventional

NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients

NCT01771705
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Dose adjust group (NFAT)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

NCT03140670
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RUCAPARIB
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

NCT07223541
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Phase 1 Interventional

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

NCT04013802
View directory record Official record
Conditions
Viral Infection
Interventions
HLA-matched VSTs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

NCT06726161
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
RYZ811, RYZ801
Diagnostic Test · Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

NCT00099268
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 4 Interventional

Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil

NCT01965925
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 30, 2026, 12:09 PM EDT
Suspended Early Phase 1 Interventional

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

NCT05620342
View directory record Official record
Conditions
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
Interventions
iC9.GD2.CAR.IL-15 T Infusion
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed No phase listed Observational

Natural Language Processing for Screening Opioid Misuse

NCT05745480
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Misuse
Interventions
Opioid Misuse Screening with an Addiction Consult Service
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
47,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 2 Interventional Results available

Optimal Treatment of Veterans With PTSD and Comorbid OUD

NCT03605342
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Opiate Use Disorder
Interventions
Buprenorphine, Cognitive Processing Therapy (CPT), Individual Drug Counseling (IDC)
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
West Haven, Connecticut • Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00696384
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Phase 1 Interventional

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT07489287
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Home Visitation Enhancing Linkages Project

NCT03750487
View directory record Official record
Conditions
Substance Use
Interventions
e-screening & brief intervention (e-SBI), Control e-SBI
Behavioral
Lead sponsor
The National Center on Addiction and Substance Abuse at Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Phase 2 Interventional

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

NCT04060017
View directory record Official record
Conditions
Autism Spectrum Disorder, Language Disorders
Interventions
Levoleucovorin Calcium, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
30 Months to 60 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Phase 1 Interventional

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

NCT07814248
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
Interventions
TS-104
Drug
Lead sponsor
TwoStep Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Maumee, Ohio • Portland, Oregon • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

NCT03538626
View directory record Official record
Conditions
HIV Antibodies
Interventions
VRC-HIVMAB091-00-AB, rHuPH20
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Phase 1 Interventional

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

NCT07007117
View directory record Official record
Conditions
Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
Interventions
PHOX2B PC-CAR T Cells
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
1 Year and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1Phase 2 Interventional

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

NCT00041808
View directory record Official record
Conditions
Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms, Lung Neoplasms, Liver Neoplasms, Cholangiocarcinoma
Interventions
MTC-DOX for Injection, Chemotherapy
Drug · Procedure
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Not applicable Interventional

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

NCT02587663
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery, Ultrasonography, Gadolinium
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 30, 2026, 12:09 PM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

NCT00443599
View directory record Official record
Conditions
Heart Defects, Congenital, Hyperglycemia
Interventions
Insulin, Usual Care
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 36 Months
Enrollment
989 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 30, 2026, 12:09 PM EDT